Revia tablets are round, white, and bear the imprint “RE-50”. In the UK they are supplied in a blister pack of 28 tablets, each representing a single daily dose.
Yes, provided you carry the original prescription label and a copy of the prescribing doctor’s note. Some countries may request proof that the medication is for a legitimate medical purpose, especially if you cross borders with large quantities.
Standard workplace drug screens typically test for opioids, cannabis, cocaine, amphetamines, and barbiturates. Naltrexone itself is not an opioid and is not usually included in routine panels, but specialised tests can detect it if requested.
Revia blocks opioid receptors, reducing alcohol-induced reward, whereas acamprosate modulates glutamate and GABA neurotransmission to stabilise brain chemistry. The two agents may be used together in some treatment plans, but they act on distinct pathways.
Small pilot studies have examined naltrexone for nicotine dependence, suggesting modest reductions in cravings. However, the evidence is insufficient for formal approval, and Revia remains an off-label option for smoking cessation.
The tablet contains microcrystalline cellulose, lactose monohydrate, magnesium stearate, and silicon dioxide. Patients with severe lactose intolerance should discuss alternatives with their prescriber.
Naltrexone has no known direct pharmacokinetic interaction with most antidepressants. Nevertheless, clinicians monitor mood changes because altering alcohol or opioid use can affect mental health.
The expiry date is printed on the packaging and is normally 24 months from the date of manufacture, provided the tablets are stored as directed.
Yes, several manufacturers produce generic naltrexone 50 mg tablets that are therapeutically equivalent to Revia and are often prescribed when cost considerations are relevant.
Take the missed tablet as soon as you remember, unless the next scheduled dose is within a few hours. In that case, skip the missed dose and continue with the regular dosing time to maintain a consistent 24-hour interval.
Revia is a brand-name medication that contains naltrexone as its sole active ingredient. It is supplied as a 50 mg oral pill and is classified in the United Kingdom as a prescription-only medicine (POM) used in the treatment of addiction. The therapeutic area is broadly termed Addiction & Quit Smoking, although the approved indications focus on alcohol dependence and opioid dependence. Revia is manufactured under licences authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and, where relevant, the European Medicines Agency (EMA).
Naltrexone is an opioid receptor antagonist. After oral ingestion, it is absorbed from the gastrointestinal tract and reaches peak plasma concentrations within 1 hour. The drug binds competitively to μ-, κ- and δ-opioid receptors, blocking the action of endogenous opioids (e.g., endorphins) and exogenous opioid substances (e.g., heroin, prescription opioids). By preventing receptor activation, naltrexone reduces the rewarding and reinforcing effects that drive substance-use behaviours.
In the context of alcohol dependence, the blockade of opioid receptors attenuates the dopamine surge in the brain’s reward pathways that normally follows alcohol consumption, thereby decreasing cravings and the likelihood of relapse. The medication has a half-life of roughly 4 hours, but its active metabolite, 6-β-naltrexol, extends pharmacological activity for up to 24 hours, allowing once-daily dosing.
Both uses are supported by the MHRA’s product licence and align with European clinical guidelines for addiction management.
Limited clinical investigations have explored naltrexone as an aid for quitting tobacco, based on its ability to modulate reward pathways linked to nicotine dependence. Current evidence is not sufficient for regulatory approval, and the use of Revia for smoking cessation remains off-label.
Disclaimer: Off-label use requires medical supervision and an individualized risk-benefit assessment. Patients should discuss any such intention with a qualified healthcare professional.
Safety Note: Patients should provide a complete medication list, including over-the-counter drugs, herbal supplements, and vitamins, to their prescriber before starting Revia.
This article provides educational information about Revia (naltrexone 50 mg) and is not a substitute for professional medical advice. Treatment decisions, including the use of the medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
